Reggie, if you read the brokers reports they are a 12 month forward estimate of the price, so mid next year. This accords with my my 12-18 month forward estimate.
NEU will most definitely not be derisked in 2-3 years. It takes closer to 5 years and A$400m to run a drug through P3 and FDA approval. Wilson’s $100 valuation is after each of the 4 indications have gone through P3 and been approved by the FDA (so after a A$1.5billion spend). It’s probably closer to 10 years away unfortunately assuming we can get the right partners (at best NEU could take 1 indication through P3).
The reality is that given positive P2 results I cannot see us remaining a stand alone company for long… NEU will be taken over.
If not, it’ll be because NNZ2591 hasn’t performed very well in which case our future valuations have been torpedoed anyway.
Share Price, page-6450
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.31 |
Change
-0.790(3.93%) |
Mkt cap ! $2.465B | |||
| Open | High | Low | Value | Volume |
| $19.86 | $19.99 | $17.97 | $22.67M | 1.196M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2222 | $19.19 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.31 | 8162 | 3 |
View Market Depth
| Last trade - 16.10pm 09/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.25 |
Change
-0.790 ( 4.18 %) |
||||
| Open | High | Low | Volume | ||
| $19.88 | $19.88 | $17.97 | 249066 | ||
| Last updated 15.59pm 09/05/2024 ? | |||||
| NEU (ASX) Chart |